- Company
- CKD to distribute·sell Bayer's 'Nexavar'·'Stivarga' in KOR
- by Kim, Jin-Gu Feb 7, 2025 05:51am
- Chong Kun Dang Pharm announced on February 6 that it has signed an exclusive sales agreement with Bayer Korea for the advanced hepatocellular carcinoma treatments 'Nexavar (sorafenib)'·'Stivarga (regorafenib).' Based on this contract, Chong Kun Dang Pharm will be responsible for exclusive distribution·sales·marketing of Nexavar and Sti
- Company
- ‘Leqvio reduces LDL-C with twice-yearly dose’
- by Son, Hyung Min Feb 7, 2025 05:51am
- While the “the lower, the better” mantra in LDL-cholesterol (LDL-C) treatment is gaining traction around the world, achieving and maintaining target levels is challenging due to the patients’ poor adherence to existing therapies. In the United States, 50% of patients who are prescribed statins stop taking them within one year, and only 5% rem
- Policy
- HIRA to develop RWE guidelines for post-listing drug evals
- by Lee, Tak-Sun Feb 7, 2025 05:51am
- The Health Insurance Review and Assessment Service (HIRA) has begun developing real-world evidence (RWE) guidelines for the evaluation of drugs listed under the post-listing drug control condition, with the goal of resolving uncertainties in the reimbursement decision-making process On the 5th, HIRA announced a request for proposals for r
- Company
- China rises as global R&D leader, K-bio not in top 50
- by Cha, Jihyun Feb 6, 2025 05:57am
- The R&D investment gap between Korean biopharmaceutical companies and Big Pharma is increasing. Analysis suggests that Korean companies must seek measures to respond to competition for next-generation technology as the R&D investment centers around the United States and China. On February 5, the Korea Chamber of Commerce and Industry (KCCI) a
- Policy
- Daewon to sell AZ’s Symbicort in Korea
- by Lee, Tak-Sun Feb 6, 2025 05:56am
- Daewon Pharmaceutical will start selling AstraZeneca's asthma inhaler Symbicort (budesonide + formoterol fumarate hydrate) in Korea. The move is expected to expand the company's asthma inhaler lineup in addition to its existing Compona and expand the company’s market share. According to industry sources, Daewon Pharmaceutical will start
- Company
- Baxter’s Renal Care Unit spinoff Vantive is launched
- by Whang, byung-woo Feb 6, 2025 05:56am
- With the acquisition process complete for Baxter's Renal Care business, it has newly launched as Vantive, a new company specializing in kidney and life-sustaining organ therapies. The spin-off follows the acquisition of Baxter's Kidney Care business by funds managed by global investment firm The Carlyle Group. As an independent company
- Company
- Imminent launch of the 3rd new CAR-T-cell therapy 'Yescarta'
- by Eo, Yun-Ho Feb 6, 2025 05:56am
- The third CAR-T-cell therapy 'Yescarta' is expected to be commercialized in South Korea. According to industry sources, Gilead Sciences submitted documentation for the approval of the CAR-T-cell therapy, Yescarta (axicabtagene ciloleucel), and the Ministry of Food and Drug Safety (MFDS) is currently conducting the review. Yescarta was
- Policy
- Imlunestrant becomes first reviewed after new drug approval
- by Lee, Hye-Kyung Feb 6, 2025 05:56am
- The first application for a new drug license has been submitted since the fee for drug approval was raised to KRW 410 million. According to industry sources on the 6th, the multinational pharmaceutical company Eli Lilly applied for an marketing authorization for its breast cancer drug 'Inrulio (imlunestrant)' to the Ministry of Food and D
- Policy
- Reimb imminent for switching between atopic dermatitis drugs
- by Lee, Tak-Sun Feb 5, 2025 05:53am
- Switching between atopic dermatitis drugs may be reimbursed soon. This is because the National Health Insurance Service has completed its review through the preliminary drug price reduction system, and all that remains is the National Health Insurance Service's negotiations. As the expected claim amount is not large, the negotiations are e
- InterView
- "High hopes for reimbursed Ilaris…a new treatment option"
- by Whang, byung-woo Feb 5, 2025 05:52am
- The Hereditary Periodic Fever (HPF) syndromes cause not just fever and pain but affect various aspects, such as patient's growth and development, psychological elements. The reimbursement coverage of a new treatment in nine years has increased patient satisfaction." Clinical practices have high hopes for changes to the treatment setting as Il
